Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

被引：0
|
作者：
le Coutre, Philipp D. [1 ]
Giles, Francis [2 ]
Hochhaus, Andreas [3 ]
Apperley, Jane F. [4 ]
Ossenkoppele, Gert [5 ]
Haque, Ariful [6 ]
Gallagher, Neil J. [7 ]
Baccarani, Michele [8 ]
Cortes, Jorge [9 ]
Kantarjian, Hagop M. [9 ]
机构：
[1] Humboldt Univ, Dept Hematol & Oncol, Charite, Berlin, Germany
[2] Univ Texas Hlth Sci Ctr San Antonio, CTRC, Inst Drug Dev, San Antonio, TX 78229 USA
[3] Univ Heidelberg, Fak Med, D-6800 Mannheim, Germany
[4] Hammersmith Hosp, Dept Hematol, London, England
[5] Vrije Univ Amsterdam, Med Ctr, Dept Hematol Br 2, Amsterdam, Netherlands
[6] Novartis Pharmaceut, Florham Pk, NJ USA
[7] Novartis Pharma AG, Oncol, Basel, Switzerland
[8] Inst Hematol & Med OncologySeragnoli, Bologna, Italy
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1108 / 1109
页数：2
相关论文
共 50 条
  • [21] A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)
    le Coutre, P.
    Gattermann, N.
    Hochhaus, A.
    Larson, R.
    Weitzman, A.
    Haque, A.
    Giles, F.
    O'Brien, S. G.
    Kantarjian, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Correlation of clinical response to nilotinib with BCR-ABL mutation status in advanced phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or intolerance
    Saglio, Giuseppe
    Kim, Dong-Wook
    Hochhaus, Andreas
    Soverini, Simona
    Erben, P.
    Branford, Susan
    Haque, Ariful
    Gallagher, Neil
    Shou, Yaping
    Hughes, Timothy
    Martinelli, G.
    Radich, Jerald
    BLOOD, 2007, 110 (11) : 576A - 577A
  • [23] Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.
    Radich, Jerald P.
    Martinelli, Giovanni
    Hochhaus, Andreas
    Gottardi, Enrico
    Soverini, Simona
    Branford, Susan
    Mueller, Martin C.
    Beppu, Lan
    Shou, Yaping
    Haque, Ariful
    Woodman, Richard C.
    Kantarjian, Hagop M.
    Hughes, Timothy P.
    Kim, Dong-Wook
    Saglio, Giuseppe
    BLOOD, 2009, 114 (22) : 464 - 465
  • [24] NILOTINIB IN CHRONIC MYELOGENOUS LEUKAEMIA IN CHRONIC PHASE (CML-CP) PATIENTS WITH IMATINIB-RESISTANCE OR INTOLERANCE: UPDATED PHASE 2 RESULTS
    Kantarjian, H. M.
    Giles, F. J.
    Bhalla, K. N.
    Larson, R. A.
    Gatterman, N.
    Ottmann, O. G.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    Le Coutre, P. H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 350 - 350
  • [25] Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study
    Kuo, Ching-Yuan
    Wang, Po-Nan
    Hwang, Wen-Li
    Tzeng, Cheng-Hwai
    Bai, Li-Yaun
    Tang, Jih-Luh
    Chang, Ming-Chih
    Lin, Sheng-Fung
    Chen, Tsai-Yun
    Chen, Yeu-Chin
    Tan, Tran-Der
    Hsieh, Chih-Yi
    Lin, Chinjune
    Lai, Clinton
    Miljkovic, Darko
    Chang, Cheng-Shyong
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (03) : 65 - 78
  • [26] Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis
    Lipton, Jeffrey H.
    le Coutre, Philipp D.
    Wang, Jim
    Yang, Mindy
    Szczudlo, Tomasz
    Giles, Francis
    BLOOD, 2008, 112 (11) : 1110 - 1110
  • [27] Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
    Giles, F. J.
    le Coutre, P. D.
    Pinilla-Ibarz, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Hochhaus, A.
    Radich, J. P.
    Saglio, G.
    Hughes, T. P.
    Martinelli, G.
    Kim, D-W
    Novick, S.
    Gillis, K.
    Fan, X.
    Cortes, J.
    Baccarani, M.
    Kantarjian, H. M.
    LEUKEMIA, 2013, 27 (01) : 107 - 112
  • [28] Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
    F J Giles
    P D le Coutre
    J Pinilla-Ibarz
    R A Larson
    N Gattermann
    O G Ottmann
    A Hochhaus
    J P Radich
    G Saglio
    T P Hughes
    G Martinelli
    D-W Kim
    S Novick
    K Gillis
    X Fan
    J Cortes
    M Baccarani
    H M Kantarjian
    Leukemia, 2013, 27 : 107 - 112
  • [29] The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP)
    Ohanian, Maro
    Kantarjian, Hagop M.
    Quintas-Cardama, Alfonso
    Jabbour, Elias J.
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Ferrajoli, Alessandra
    Kadia, Tapan M.
    O'Brien, Susan
    Cortes, Jorge E.
    BLOOD, 2012, 120 (21)
  • [30] MINIMAL CROSS-INTOLERANCE BETWEEN NILOTINIB AND IMATINIB IN PATIENTS WITH IMATINIB-INTOLERANT CHRONIC MYELOGENOUS LEUKAEMIA (CML) IN CHRONIC PHASE (CP) OR ACCELERATED PHASE (AP)
    Hochhaus, A.
    Kantarjian, H. M.
    Baccarani, M.
    Le Coutre, P.
    Haque, A.
    Gallagher, N.
    Cortes, J.
    Giles, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 56 - 57
12345